PHAT (STOCKS)
Phathom Pharmaceuticals, Inc. Common Stock
$12.670000
+0.040000 (+0.32%)
Prev close: $12.630000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Steven L. Basta
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $998.38M
- Employees
- 427
- P/E (TTM)
- -4.15
- P/B (TTM)
- -2.07
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.29 | $-0.39 | +0.0991 | +25.47% |
|
Sep 2025 (Q3)
|
$-0.41 | $-0.56 | +0.1459 | +26.25% |
|
Jun 2025 (Q2)
|
$-1.05 | $-1.06 | +0.0108 | +1.02% |
|
Mar 2025 (Q1)
|
$-1.31 | $-1.17 | -0.1404 | -12.00% |
Financial Statements
| Revenues | $175.11M |
| Benefits Costs and Expenses | $396.36M |
| Cost Of Revenue | $22.60M |
| Costs And Expenses | $396.36M |
| Gross Profit | $152.51M |
| Nonoperating Income/Loss | -$61.26M |
| Operating Expenses | $312.50M |
| Selling, General, and Administrative Expenses | $279.72M |
| Depreciation and Amortization | $600.00K |
| Research and Development | $32.78M |
| Operating Income/Loss | -$159.99M |
| Income/Loss From Continuing Operations After Tax | -$221.25M |
| Income/Loss From Continuing Operations Before Tax | -$221.25M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$221.25M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$221.25M |
| Net Income/Loss Available To Common Stockholders, Basic | -$221.25M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.03 |
| Diluted Earnings Per Share | -$3.03 |
| Basic Average Shares | 72,918,764 |
| Diluted Average Shares | 72,918,764 |
| Assets | $259.15M |
| Current Assets | $228.97M |
| Accounts Receivable | $78.13M |
| Inventory | $5.52M |
| Other Current Assets | $145.33M |
| Noncurrent Assets | $30.18M |
| Fixed Assets | $1.06M |
| Other Non-current Assets | $29.11M |
| Liabilities | $697.32M |
| Current Liabilities | $132.04M |
| Accounts Payable | $4.98M |
| Other Current Liabilities | $127.06M |
| Noncurrent Liabilities | $565.27M |
| Long-term Debt | $209.09M |
| Other Non-current Liabilities | $356.19M |
| Equity | -$438.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$438.17M |
| Liabilities And Equity | $259.15M |
| Net Cash Flow From Operating Activities | -$166.78M |
| Net Cash Flow From Operating Activities, Continuing | -$166.78M |
| Net Cash Flow From Investing Activities | -$229.00K |
| Net Cash Flow From Investing Activities, Continuing | -$229.00K |
| Net Cash Flow From Financing Activities | -$288.00K |
| Net Cash Flow From Financing Activities, Continuing | -$288.00K |
| Net Cash Flow | -$167.29M |
| Net Cash Flow, Continuing | -$167.29M |
| Comprehensive Income/Loss | -$221.25M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$221.25M |
| Other Comprehensive Income/Loss | $0.00 |